Literature DB >> 24518097

Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor?

Toyokawa Gouji1, Seto Takashi, Takenoyama Mitsuhiro, Ichinose Yukito.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24518097     DOI： 10.1097/JTO.0000000000000113

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  30 in total

1.  Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.

Authors:  Justin F Gainor; Daniel S W Tan; Tomasso De Pas; Benjamin J Solomon; Aziah Ahmad; Chiara Lazzari; Filippo de Marinis; Gianluca Spitaleri; Katherine Schultz; Luc Friboulet; Beow Y Yeap; Jeffrey A Engelman; Alice T Shaw
Journal:  Clin Cancer Res       Date:  2015-02-27       Impact factor: 12.531

2.  Pharmacologic characterization of CT-711, a novel dual inhibitor of ALK and c-Met.

Authors:  Lei Wang; Mingzhao Gao; Mengya Tong; Chengying Xie; Ye He; Li Fu; Yun Li; Haoyu Fu; Liguang Lou
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

3.  Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.

Authors:  Aaron N Hata; Alice T Shaw; Satoshi Yoda; Jessica J Lin; Michael S Lawrence; Benjamin J Burke; Luc Friboulet; Adam Langenbucher; Leila Dardaei; Kylie Prutisto-Chang; Ibiayi Dagogo-Jack; Sergei Timofeevski; Harper Hubbeling; Justin F Gainor; Lorin A Ferris; Amanda K Riley; Krystina E Kattermann; Daria Timonina; Rebecca S Heist; A John Iafrate; Cyril H Benes; Jochen K Lennerz; Mari Mino-Kenudson; Jeffrey A Engelman; Ted W Johnson
Journal:  Cancer Discov       Date:  2018-04-12       Impact factor: 39.397

Review 4.  Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.

Authors:  Ryohei Katayama; Christine M Lovly; Alice T Shaw
Journal:  Clin Cancer Res       Date:  2015-05-15       Impact factor: 12.531

5.  Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?

Authors:  Alice Mogenet; Pascale Tomasini; Laurent Greillier; Fabrice Barlesi
Journal:  Transl Lung Cancer Res       Date:  2019-12

6.  Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

Authors:  Ted W Johnson; Jeffrey A Engelman; Alice T Shaw; Luc Friboulet; Ignaty Leshchiner; Justin F Gainor; Simon Bergqvist; Alexei Brooun; Benjamin J Burke; Ya-Li Deng; Wei Liu; Leila Dardaei; Rosa L Frias; Kate R Schultz; Jennifer Logan; Leonard P James; Tod Smeal; Sergei Timofeevski; Ryohei Katayama; A John Iafrate; Long Le; Michele McTigue; Gad Getz
Journal:  N Engl J Med       Date:  2015-12-23       Impact factor: 91.245

Review 7.  Resisting Resistance: Targeted Therapies in Lung Cancer.

Authors:  Jessica J Lin; Alice T Shaw
Journal:  Trends Cancer       Date:  2016-07

Review 8.  Targeting ALK: Precision Medicine Takes on Drug Resistance.

Authors:  Jessica J Lin; Gregory J Riely; Alice T Shaw
Journal:  Cancer Discov       Date:  2017-01-25       Impact factor: 39.397

Review 9.  Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it.

Authors:  M Drizou; E A Kotteas; N Syrigos
Journal:  Clin Transl Oncol       Date:  2017-01-04       Impact factor: 3.405

Review 10.  MET-dependent solid tumours - molecular diagnosis and targeted therapy.

Authors:  Robin Guo; Jia Luo; Jason Chang; Natasha Rekhtman; Maria Arcila; Alexander Drilon
Journal:  Nat Rev Clin Oncol       Date:  2020-06-08       Impact factor: 66.675
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.